Bowel Cancer Breakthrough: Immunotherapy Trial Reports Zero Relapses After Three Years
A landmark clinical trial is challenging the standard of care for specific types of bowel cancer, suggesting that a targeted approach to immunotherapy before surgery could be significantly more effective than traditional post-operative chemotherapy. New data from the NEOPRISM-CRC trial reveals that patients treated with this method remained cancer-free after nearly three years of follow-up.
The findings, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, indicate a potential shift in how clinicians manage stage two and three bowel cancer. By prioritizing the immune system’s ability to attack the tumor before surgical removal, researchers have observed a level of durable cancer control that far exceeds current expectations.
The NEOPRISM-CRC Trial: A New Approach to Treatment
Led by a research team from University College London (UCL) and University College London Hospitals (UCLH), the NEOPRISM-CRC trial investigated the impact of neoadjuvant (pre-operative) immunotherapy. Instead of the traditional route—surgery followed by chemotherapy—eligible patients received a short course of immunotherapy using the drug pembrolizumab.
The treatment protocol involved nine weeks of pembrolizumab administered before the planned bowel cancer operation. This strategy aimed to shrink the tumor and prime the immune system to identify and destroy any remaining cancer cells throughout the body, reducing the likelihood of the disease returning.
Zero Relapses: Comparing Results to Standard Care
The results of the follow-up study are striking. After 33 months, none of the treated patients in the trial experienced a return of their cancer. This zero-relapse rate includes both patients who showed no signs of disease immediately after their operation and those who had small amounts of cancer remaining that simply did not grow or spread during the observation period.
To put these results in perspective, clinicians typically expect around 25% of patients receiving the standard combination of surgery and post-operative chemotherapy to relapse within three years. The NEOPRISM-CRC data suggests that for this specific type of bowel cancer, pre-surgery immunotherapy provides more durable and long-lasting control.
Precision Medicine and Personalized Monitoring
Beyond survival rates, the research team focused on the “why” behind the treatment’s success. By analyzing blood samples, researchers developed personalized blood tests designed to monitor the patient’s response in real-time.
These diagnostic tools allow doctors to determine early on whether the immunotherapy is working and whether any residual cancer remains in the bloodstream. This level of precision helps clinicians identify which patients are most likely to benefit from the treatment, moving away from a “one size fits all” approach to oncology.
- Treatment Shift: Patients received nine weeks of pembrolizumab before surgery instead of chemotherapy after surgery.
- Exceptional Outcomes: Zero relapses were reported after 33 months of follow-up.
- Comparison: The results outperform the typical 25% relapse rate associated with standard surgery and chemotherapy.
- Patient Group: The trial focused on patients with stage two or three bowel cancer of a specific type.
- Early Detection: Personalized blood tests were developed to track treatment efficacy and detect residual cancer.
Frequently Asked Questions
Who is eligible for this immunotherapy treatment?
The trial specifically targeted patients with stage two or three bowel cancer of a particular type. Immunotherapy is not effective for all bowel cancers; it typically requires specific biomarkers that allow the drug pembrolizumab to trigger an immune response against the tumor.
How does this differ from standard chemotherapy?
Standard chemotherapy is often administered after surgery to kill any remaining microscopic cancer cells. In contrast, this immunotherapy approach is administered before surgery to shrink the primary tumor and train the immune system to provide long-term surveillance against recurrence.
Is this treatment available to the general public?
These results stem from the NEOPRISM-CRC clinical trial. While the data is highly promising, such treatments usually undergo further large-scale validation before becoming the standard clinical guideline for all eligible patients.
Looking Ahead
The success of the NEOPRISM-CRC trial marks a significant step toward personalized cancer care. By combining targeted immunotherapy with innovative blood-based monitoring, the medical community is moving closer to a future where bowel cancer treatment is tailored to the individual’s biological profile, potentially eliminating the need for toxic post-operative chemotherapy in a significant number of patients.